Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006.
ABSTRACT Studies show that a large proportion of adults with high levels of low-density lipoprotein cholesterol (LDL-C) remain untreated or undertreated despite growing use of lipid-lowering medications.
To investigate trends in screening prevalence, use of cholesterol-lowering medications, and LDL-C levels across 4 study cycles (1999-2000, 2001-2002, 2003-2004, and 2005-2006).
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, stratified, multistage probability sample survey of the US civilian, noninstitutionalized population. After we restricted the study sample to fasting participants aged 20 years or older (n = 8018) and excluded pregnant women (n = 464) and participants with missing data (n = 510), our study sample consisted of 7044 participants.
High LDL-C levels, defined as levels above the specific goal for each risk category outlined in guidelines from the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). All presented results are weighted and age-standardized to 2000 standard population estimates.
Prevalence of high LDL-C levels among persons aged 20 years or older decreased from 31.5% in 1999-2000 to 21.2% in 2005-2006 (P < .001 for linear trend) but varied by risk category. By the 2005-2006 study cycle, prevalence of high LDL-C was 58.9%, 30.2%, and 11.0% for high-, intermediate-, and low-risk categories, respectively. Self-reported use of lipid-lowering medications increased from 8.0% to 13.4% (P < .001 for linear trend), but screening rates did not change significantly, remaining less than 70% (P = .16 for linear trend) during the study periods.
Among the NHANES population aged 20 years or older, the prevalence of high LDL-C levels decreased from 1999-2000 to 2005-2006. In the most recent period, the prevalence was 21.2%.
Full-textDOI: · Available from: Elena Kuklina, Jun 17, 2015
- SourceAvailable from: sciencedirect.com[Show abstract] [Hide abstract]
ABSTRACT: Existing treatments are inadequate for patients at high risk of coronary heart disease caused by elevated levels of plasma low-density lipoprotein cholesterol (LDL-C). Bambuterol is a prodrug of β2-agonist commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) with the advantage of once daily dosing and favorable side effect profile. The potential lipid-lowering effects of bambuterol were unclear, possibly due to the racemic bambuterol (rac-bambuterol) that was used in previous studies.02/2015; 251(4). DOI:10.1016/j.ebiom.2015.02.006
- [Show abstract] [Hide abstract]
ABSTRACT: Validated guidelines to manage low-density lipoprotein (LDL)-cholesterol are utilized inconsistently or not at all even though their application lowers the incidence of coronary events. New approaches are needed, therefore, to implement these guidelines in everyday practice. We compared an automated method for applying The National Cholesterol Education Panel (NCEP) guidelines with results from routine care for managing LDL-cholesterol. The automated method comprised computerized history-taking and analysis of historical data without physician input. Results from routine care were determined for 213 unselected patients and compared with results from interviews of the same 213 patients by a computerized history-taking program. Data extracted from hospital charts showed that routine care typically did not collect sufficient information to stratify risk and assign treatment targets for LDL-cholesterol and that there were inconsistencies in identifying patients with normal or elevated levels of LDL-cholesterol in relation to risk. The computerized interview program outperformed routine care in collecting historical data relevant to stratifying risk, assigning treatment targets, and clarifying the presence of hypercholesterolemia relative to risk. Computerized history-taking coupled with automated analysis of the clinical data can outperform routine medical care in applying NCEP guidelines for stratifying risk and identifying patients with hypercholesterolemia in relation to risk.Vascular Health and Risk Management 11/2010; 6:1039-46. DOI:10.2147/VHRM.S14302
- [Show abstract] [Hide abstract]
ABSTRACT: The paper by Lei et al. in this issue adds to the growing body of empirical evidence that education and cognitive stimulation, both in early-life and in later-life, seem especially important for cognitive health and the prevention of cognitive decline with aging. The expanding educational opportunities for girls and women in developing countries such as China over the last few decades appear to have played an important role in improving their cognitive health and, in turn, have likely expanded their opportunities to participate more fully and successfully in both work and social roles. While “curing” dementia in the coming decades seems unlikely, decreasing the risk of cognitive impairment and disability in both developed and developing countries through increasing education, life-long cognitive stimulation, and improved control of cardiovascular risk appears achievable. Success would benefit people of all ages by keeping older adults more independent and productive, and minimizing the burden of support on younger generations.08/2014; DOI:10.1016/j.jeoa.2014.08.001